Identification of critical extracellular loop residues involved in alpha 1-adrenergic receptor subtype-selective antagonist binding

MM Zhao, J Hwa and DM Perez

Department of Molecular Cardiology, Cleveland Clinic Research Institute, Ohio 44195, USA.

alpha 1-Adrenergic receptor (AR) subtypes mediate many effects of the sympathetic nervous system. Although structurally similar, the three cloned subtypes (alpha 1a-AR, alpha 1b-AR, and alpha 1d-AR) bind a series of ligands with different relative potencies. This is particularly true for the alpha 1a-AR, which recognizes a number of ligands with 10-100-fold higher affinity than the alpha 1b or alpha 1d subtypes. Because ligands are hypothesized to bind to receptor residues that are located in the transmembrane (TM) spanning domains, subtype differences in ligand recognition are likely the result of differences in the binding properties of nonconserved TM residues. We previously reported on the identification of two TM residues in the alpha 1b-AR that converted the agonist binding profile entirely to that of the alpha 1a-AR when mutated to corresponding alpha 1a-AR residues. We now report on the determinants of antagonist selectivity between these two alpha 1-AR subtypes. Construction of a chimera in which the entire fifth TM and a portion of the putative second extracellular loop of the hamster alpha 1b-AR was replaced with the corresponding region of the rat alpha 1a-AR revealed that the chimera accounted for all of the higher binding affinity (8-29-fold) seen in the alpha 1a-AR for two antagonists, phentolamine and WB4101. Using site-directed mutagenesis, we further analyzed individual point mutations making up this chimera. We found that three adjacent residues, which were located on the extracellular loop of the fifth TM, are fully responsible for this higher antagonist binding affinity in the alpha 1a-AR. These three point mutations (G196Q, V1971, T198N) in the alpha 1b-AR were additive and sufficient in their effects on changing antagonist-binding profiles to that of the alpha 1a-AR. Reversal of these three residues in the alpha 1a-AR to their corresponding residues in the alpha 1b-AR completely reversed the antagonist affinity to wild-type alpha 1b-AR values. To aid in molecular modeling, the use of organic chemicals that mimic key structures of the antagonists were used in competitive ligand- binding studies with the mutated receptors. These results indicated the orientation of both phentolamine and WB4101 in the alpha 1-AR binding pocket. Together, the data indicate that alpha 1-antagonists may bind near the surface of the receptor, much like the peptide hormone receptors, and not deep within the TM regions, where the ligand-binding pocket was first proposed and identified for alpha 1 agonists.

Volume 50, Issue 5, pp. 1118-1126, 11/01/1996
Copyright © 1996 by American Society for Pharmacology and Experimental Therapeutics

This article has been cited by other articles:

				A. Strasser, H.-J. Wittmann, and R. Seifert Ligand-Specific Contribution of the N Terminus and E2-Loop to Pharmacological Properties of the Histamine H1-Receptor J. Pharmacol. Exp. Ther., September 1, 2008; 326(3): 783 - 791. [Abstract] [Full Text] [PDF]

				M. Conner, S. R. Hawtin, J. Simms, D. Wootten, Z. Lawson, A. C. Conner, R. A. Parslow, and M. Wheatley Systematic Analysis of the Entire Second Extracellular Loop of the V1a Vasopressin Receptor: KEY RESIDUES, CONSERVED THROUGHOUT A G-PROTEIN-COUPLED RECEPTOR FAMILY, IDENTIFIED J. Biol. Chem., June 15, 2007; 282(24): 17405 - 17412. [Abstract] [Full Text] [PDF]

				S. R. Hawtin, J. Simms, M. Conner, Z. Lawson, R. A. Parslow, J. Trim, A. Sheppard, and M. Wheatley Charged Extracellular Residues, Conserved throughout a G-protein-coupled Receptor Family, Are Required for Ligand Binding, Receptor Activation, and Cell-surface Expression J. Biol. Chem., December 15, 2006; 281(50): 38478 - 38488. [Abstract] [Full Text] [PDF]

				H. Lan, C. J. DuRand, M. M. Teeter, and K. A. Neve Structural Determinants of Pharmacological Specificity Between D1 and D2 Dopamine Receptors Mol. Pharmacol., January 1, 2006; 69(1): 185 - 194. [Abstract] [Full Text] [PDF]

				S. Tunaru, J. Lattig, J. Kero, G. Krause, and S. Offermanns Characterization of Determinants of Ligand Binding to the Nicotinic Acid Receptor GPR109A (HM74A/PUMA-G) Mol. Pharmacol., November 1, 2005; 68(5): 1271 - 1280. [Abstract] [Full Text] [PDF]

				A. Kukkonen, M. Perakyla, K. E. O. Akerman, and J. Nasman Muscarinic Toxin 7 Selectivity Is Dictated by Extracellular Receptor Loops J. Biol. Chem., December 3, 2004; 279(49): 50923 - 50929. [Abstract] [Full Text] [PDF]

				Z. Chen, G. Rogge, C. Hague, D. Alewood, B. Colless, R. J. Lewis, and K. P. Minneman Subtype-selective Noncompetitive or Competitive Inhibition of Human {alpha}1-Adrenergic Receptors by {rho}-TIA J. Biol. Chem., August 20, 2004; 279(34): 35326 - 35333. [Abstract] [Full Text] [PDF]

				D. Yin, S. Gavi, H.-y. Wang, and C. C. Malbon Probing Receptor Structure/Function with Chimeric G-Protein-Coupled Receptors Mol. Pharmacol., June 1, 2004; 65(6): 1323 - 1332. [Abstract] [Full Text] [PDF]

				L. Shi and J. A. Javitch The second extracellular loop of the dopamine D2 receptor lines the binding-site crevice PNAS, January 13, 2004; 101(2): 440 - 445. [Abstract] [Full Text] [PDF]

				M. T. Piascik and D. M. Perez alpha 1-Adrenergic Receptors: New Insights and Directions J. Pharmacol. Exp. Ther., August 1, 2001; 298(2): 403 - 410. [Abstract] [Full Text] [PDF]

				J. A. Ballesteros, L. Shi, and J. A. Javitch Structural Mimicry in G Protein-Coupled Receptors: Implications of the High-Resolution Structure of Rhodopsin for Structure-Function Analysis of Rhodopsin-Like Receptors Mol. Pharmacol., July 1, 2001; 60(1): 1 - 19. [Abstract] [Full Text]

				D. J. J. Waugh, M.-M. Zhao, M. J. Zuscik, and D. M. Perez Novel Aromatic Residues in Transmembrane Domains IV and V Involved in Agonist Binding at alpha 1a-Adrenergic Receptors J. Biol. Chem., April 14, 2000; 275(16): 11698 - 11705. [Abstract] [Full Text] [PDF]

				U. Gether Uncovering Molecular Mechanisms Involved in Activation of G Protein-Coupled Receptors Endocr. Rev., February 1, 2000; 21(1): 90 - 113. [Abstract] [Full Text]

				J. A. Schetz, P. S. Benjamin, and D. R. Sibley Nonconserved Residues in the Second Transmembrane-Spanning Domain of the D4 Dopamine Receptor Are Molecular Determinants of D4-Selective Pharmacology Mol. Pharmacol., January 1, 2000; 57(1): 144 - 152. [Abstract] [Full Text]

				J. E. Porter and D. M. Perez Characteristics for a Salt-bridge Switch Mutation of the alpha 1b Adrenergic Receptor. ALTERED PHARMACOLOGY AND RESCUE OF CONSTITUTIVE ACTIVITY J. Biol. Chem., December 3, 1999; 274(49): 34535 - 34538. [Abstract] [Full Text] [PDF]

				K. Wieland, A. M. T. Laak, M. J. Smit, R. Kuhne, H. Timmerman, and R. Leurs Mutational Analysis of the Antagonist-binding Site of the Histamine H1 Receptor J. Biol. Chem., October 15, 1999; 274(42): 29994 - 30000. [Abstract] [Full Text] [PDF]

				C. Hoffmann, S. Moro, R. A. Nicholas, T. K. Harden, and K. A. Jacobson The Role of Amino Acids in Extracellular Loops of the Human P2Y1 Receptor in Surface Expression and Activation Processes J. Biol. Chem., May 21, 1999; 274(21): 14639 - 14647. [Abstract] [Full Text] [PDF]

				T. Wurch, F. C. Colpaert, and P. J. Pauwels Chimeric Receptor Analysis of the Ketanserin Binding Site in the Human 5-Hydroxytryptamine1D Receptor: Importance of the Second Extracellular Loop and Fifth Transmembrane Domain in Antagonist Binding Mol. Pharmacol., December 1, 1998; 54(6): 1088 - 1096. [Abstract] [Full Text]

				M.-M. Zhao, R. J. Gaivin, and D. M. Perez The Third Extracellular Loop of the beta 2-Adrenergic Receptor Can Modulate Receptor/G Protein Affinity Mol. Pharmacol., March 1, 1998; 53(3): 524 - 529. [Abstract] [Full Text]

				D. J. J. Waugh, R. J. Gaivin, M. J. Zuscik, P. Gonzalez-Cabrera, S. A. Ross, J. Yun, and D. M. Perez Phe-308 and Phe-312 in Transmembrane Domain 7 Are Major Sites of alpha 1-Adrenergic Receptor Antagonist Binding. IMIDAZOLINE AGONISTS BIND LIKE ANTAGONISTS J. Biol. Chem., June 29, 2001; 276(27): 25366 - 25371. [Abstract] [Full Text] [PDF]